FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to neurology and ophthalmology, and can be used for prediction of development of neurodegenerative diseases in mice, in the basis of pathogenesis of which lies γ-synucleinopathy. An intraocular pressure (IOP) is determined before and after the instillation in the conjunctival cavity of melatonin 0.1 %, or haloperidol 0.2 %, or dopamine 10 %. If the IOP decreases more than 4 mm Hg for more than 1 hour, developing neurodegenerative diseases are predicted along γ-synucleinopathy.
EFFECT: method provides formation of risk groups of developing neurodegenerative diseases and determination of possible tactics of preventive measures due to definition of IOP in mice before and after single instillation of one of regulators of dopaminergic system: dopamine, haloperidol, melatonin.
1 cl, 3 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2722666C1 |
METHOD OF EXPERIMENTAL TREATMENT OF EYE NEURODEGENERATIVE PROCESS | 2023 |
|
RU2794835C1 |
ALPHA-SYNUCLEIN MODULATORS | 2018 |
|
RU2797677C2 |
METHOD FOR MODELING THE NEURODEGENERATIVE PROCESS IN THE EYE | 2022 |
|
RU2787515C1 |
PROTOFIBRIL-BINDING ANTIBODIES AND USE THEREOF IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, DEMENTIA WITH LEWY BODIES AND OTHER ALPHA-SYNUCLEINOPATHIES | 2011 |
|
RU2555526C2 |
METHOD OF REDUCING INTRAOCULAR PRESSURE | 2011 |
|
RU2472471C1 |
AGENT FOR REDUCING INTRAOCULAR PRESSURE AND METHOD OF USE THEREOF | 2022 |
|
RU2815996C1 |
PSYCHOTIC DISORDER SIMULATION METHOD | 2004 |
|
RU2366464C2 |
METHOD FOR DIAGNOSTICS OF PARKINSON'S DISEASE | 2017 |
|
RU2657763C1 |
METHOD FOR TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA | 0 |
|
SU1648452A1 |
Authors
Dates
2019-10-16—Published
2018-12-13—Filed